Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

Inclusion criteria

• Male patients aged from 18 to 75 years old;
• The patients' ECOG score ≤ 2;
• Prostate cancer patients in castration resistance stage (with or without distant metastasis):
• Previous new endocrine therapy is ineffective;
• Past treatment with too much citabine or cabatase is ineffective.
• Have measurable or evaluable lesions;
• The patients' main tissues and organs function well:
• Liver function: ALT/AST \< 3 times the upper limit of normal value (ULN);
• renal function: creatinine \< 220 μ mol/L;
• Lung function: indoor oxygen saturation ≥ 95%;
• Cardiac function: Left ventricular ejection fraction (LVEF)≥40%
• Patients or their legal guardians voluntarily participate and sign the informed consent form.

Exclusion criteria

• Infectious diseases (such as HIV, active hepatitis B or C infection, active tuberculosis, etc.);
• Feasibility evaluation screening proves that the transfection of targeted lymphocytes is less than 10% or the amplification under the co-stimulation of CD3/CD28 is insufficient (\< 5 times);
• The vital signs are abnormal and those who cannot cooperate with the inspectors;
• Those with mental illness or mental illness who can't cooperate with treatment and curative effect evaluation;
• Highly allergic constitution or severe allergic history, especially those who are allergic to IL-2;
• Subjects with systemic infection or local severe infection who need anti-infection treatment;
• Complicated dysfunction of heart, lung, brain, liver, kidney and other important organs;
• Patients with other tumors;
• Doctors think that there are other reasons that can't be included in the treatment.